This is much lower than the risk conferred by the portion of N-acetyltransferase 2 (NAT2) slow acetylators reported in the first studies on bladder cancer risk due to high exposure to highly carcinogenic aromatic amines in the chemical industry at that time (Lewalter and Miksche, 1992[24]; Cartwright et al., 1982[3]; Golka et al., 2002[10]) or conferred by the portion of GSTM1 negatives reported formerly in highly industrialized areas (Golka et al., 1998[9]; Hung et al., 2004[16]). The gene discussed is GSTM1; the disease is urinary bladder carcinoma.